Mass Device

Already worth billions of dollars, the global surgical robotics market is expected to double in value over the rest of the decade. MassDevice’s free Surgical Robotics Market Special Reportprovides a detailed market forecast, including sales growth forecasts for the individual companies in the space including Intuitive Surgical, Stryker, Zimmer Biomet, Globus Medical, Smith+Nephew, and more.

The multi-billion dollar CGM market is expected to experience substantial, double-digit percentage growth over the next five years. MassDevice’s free CGM Market Special Report provides a detailed market forecast, including CGM sales growth forecasts for the individual companies in the space including Abbott, Dexcom, Medtronic and Senseonics.

A screengrab from a Corify video of its Acorys cardiac mapping technology. Corify Care announced today that it received FDA clearance for its Acorys imageless, non-invasive cardiac mapping platform. Madrid-based Corify designed its platform to provide a global, four-chamber view of cardiac electrical activity in real time. It combines high-resolution 3D anatomical models with real-time electrical activity to introduce true 4D mapping.

The ExaStim spinal cord stimulation system [Image courtesy of Aneuvo] Aneuvo announced that it received FDA clearance for its ExaStim spinal cord stimulation (SCS) system. Los Angeles-based Aneuvo designed ExaStim to deliver non-invasive, personalized transcutaneous SCS therapy. It supports functional neurorehabilitation for patients paralysis due to spinal cord injury (SCI).

GE HealthCare (Nasdaq:GEHC) announced that it expanded its ongoing collaboration with RadNet subsidiary DeepHealth. The companies hope to further the innovation, commercialization and adoption of AI-powered mammography tools. Chicago-based GE HealthCare said the announcement coincides with the Society of Breast Imaging (SBI) Annual Symposium in Seattle this week.

[Image courtesy of Zimmer Biomet] Zimmer Biomet (NYSE:ZBH) announced that it received FDA 510(k) clearance for a line extension to its existing Identity and Comprehensive shoulder systems. The clearance expands the existing capabilities for the Identity shoulder system and Comprehensive reverse shoulder systems with additional implant sizes and matching surgical tools. It aims to enable surgeons to treat a wider range of patient statures.

The Tigertriever thrombectomy device [Image courtesy of Rapid Medical] Rapid Medical announced today that it received FDA clearance for the Tigertriever 25 thrombectomy device, its latest addition to the platform. The company also reported the first clinical cases using the device in treating large vessel occlusion (LVO) stroke. Designed specifically for large clot burden in proximal vessels, Tigertriever 25 combines a 53 mm capture length with proprietary real-time force control.

The Verida spectral CT system. [Image courtesy of Philips] Philips (NYSE:PHG) announced today that it received FDA 510(k) clearance for its AI-powered Spectral CT Verida system. The company touts Verida as the world’s first detector-based spectral CT fully powered by AI. Amsterdam-based Philips unveiled the technology in December 2025. Philips designed Verida to transform CT imaging, using AI to optimize the entire imaging chain.

Abbott (NYSE:ABT) today posted first-quarter financial results that came in ahead of the consensus sales forecast on Wall Street. The company retained its prior sales guidance for between 6.5% and 7.5% growth in 2026. However, Abbott cut its adjusted earnings per share (EPS) guidance from $5.55-$5.80 to $5.38-$5.58, which includes $0.20 of dilution related to the recently completed $21 billion acquisition of Exact Sciences. Shares of ABT fell 4.2% to $97.25 apiece before the market opened today.

The Trilogy Evo ventilator [Image courtesy of Philips] Philips (NYSE:PHG) has issued corrections for some of its Trilogy Evo ventilator platforms due to multiple issues. An FDA notice issued on April 15, 2026, states that the company issued a correction — not a removal — for its Trilogy Evo, Trilogy EV300, Trilogy O2 and Trilogy Evo Universal ventilators. Still, the FDA identified the recall as its most serious type.